The battle for users rages on in social media. The big players in the industry all released a number of new products, and some, like Snapchat, unveiled redesigns to draw people in. Did it pay off? Diply President Dan Lagani takes a look at the winners and losers in 2017. Diply conducted a survey looking at how people are using social media apps and sites. Facebook, unsurprisingly, came out on top as the most popular platform. What is surprising, however, is that millennials are 45 times more likely to use Facebook than Twitter, and that lead is expected to grow. When asked which platform they would be most likely to delete in 2018, respondents put LinkedIn at the top of their list. Following closely behind were Twitter and Snapchat. After Snap's major revenue miss this year, the company needs a big boost to turn things around in the new year.

Share:
More In Business
Poll: More Americans think companies benefit from legal immigration
A new poll finds U.S. adults are more likely than they were a year ago to think immigrants in the country legally benefit the economy. That comes as President Donald Trump's administration imposes new restrictions targeting legal pathways into the country. The Associated Press-NORC Center for Public Affairs Research survey finds Americans are more likely than they were in March 2024 to say it’s a “major benefit” that people who come to the U.S. legally contribute to the economy and help American companies get the expertise of skilled workers. At the same time, perceptions of illegal immigration haven’t shifted meaningfully. Americans still see fewer benefits from people who come to the U.S. illegally.
Tylenol maker rebounds a day after unfounded claims about its safety
Shares of Tylenol maker Kenvue are bouncing back sharply before the opening bell a day after President Donald Trump promoted unproven and in some cases discredited ties between Tylenol, vaccines and autism. Trump told pregnant women not to use the painkiller around a dozen times during the White House news conference Monday. The drugmaker tumbled 7.5%. Shares have regained most of those losses early Tuesday in premarket trading.
Load More